重启后首家获受理！高瓴入股

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (Tainuo Maibo) has submitted its IPO application to the Shanghai Stock Exchange, marking the first company accepted under the newly restarted fifth set of listing standards on the Sci-Tech Innovation Board [1][3]. Company Overview - Tainuo Maibo, established in 2015, is an innovative biopharmaceutical company focused on the development of monoclonal antibody drugs. Its core product, Staidotamab Injection (New Timo®), is the world's first recombinant anti-tetanus toxin monoclonal antibody drug, approved for market in February 2025. It is recognized as a breakthrough therapy by the National Medical Products Administration (NMPA) and has received "Fast Track" designation from the FDA [3]. Financial Performance - The company has reported continuous net losses since its establishment, with losses recorded for the years 2022, 2023, 2024, and the first quarter of 2025. As of March 31, 2025, Tainuo Maibo's cumulative unabsorbed losses amounted to 1.024 billion yuan [3]. Institutional Investor Involvement - Tainuo Maibo is the first company to apply the senior professional institutional investor system, with Hillhouse Capital's subsidiary, Hillhouse Chenjun, holding 3.94% of the company's shares prior to the IPO application [3][4]. The senior professional institutional investor system aims to leverage the expertise of experienced investment institutions to enhance the review process [4]. Regulatory Framework - The introduction of the senior professional institutional investor system is a pilot program specifically for companies applying under the fifth set of standards. This system is not a new listing requirement but serves as a reference for the review process [5].